Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 59 clinical trials
None
Saracatinib Trial TO Prevent FOP

This is a phase 2 study, designed as a European multicentre 6-month double blind random-ized controlled trial (RCT) of AZD0530 versus matched placebo, followed by a 12 month trial comparing open-label extended AZD0530 treatment with historical control data. Study population: Male and female adult patients aged 18 years and older …

  • 0 views
  • 25 Jan, 2021
  • 3 locations
None
Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis

The use of lipid lowering agents in patients with idiopathic inflammatory myopathies is controversial. Therefore, the aim of the present study is to assess clinically and laboratory the impact

polymyositis
  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level

. By the way, statin is used in restricted groups of rheumatologists due to awareness of side effects; myositis and hepatitis, that are frequently found in SLE patients more so than other

myositis
autoimmune disease
corticosteroids
  • 51 views
  • 07 Nov, 2020
  • 1 location
None
The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients

Anti-melanoma differentiation-associated gene5 (Anti-MDA5) antibody positive Dermatomyositis (DM) is a subtype of DM that is more frequent in East Asia, which is often exhibit skin lesion, clinically amyopathic and interstitial lung disease. About 42%-100% of patients with Anti-MDA5+ DM develop rapidly progressive interstitial lung disease (RPILD) and result in respiratory …

  • 0 views
  • 31 Jul, 2021
  • 1 location
None
Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

This is a phase 2, pilot, randomized, placebo-controlled trial of Gamunex-C IVIG as mono-therapy for HMGCoA reductase auto-antibody positive (HMGCR) necrotizing myopathy. The trial will test the feasibility and initial efficacy of Gamunex-C IVIG mono-therapy in HMGCR necrotizing myopathy.

  • 0 views
  • 24 Sep, 2021
  • 1 location
None
Intraorbital Injection Versus Oral Steroid in Anterior Idiopathic Orbital Inflammation

A multicenter randomised double-arm clinical trial, to compare safety and efficacy of oral versus intralesional injection of steroid in a group of patients suffering from idiopathic orbital inflammation is designed. Outcome measures include number of recurrences, duration of remission, and side effects.

  • 0 views
  • 08 Jul, 2021
  • 1 location
None
Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

Summary: Background: There is a lot of interest in the function and role of HDL to prevent and mitigate atherosclerosis in patients who are at or near LDLc targets. Statins have variable effects on HDLc which are accentuated in patients with a low baseline HDLc. Higher doses of statins are …

  • 1 views
  • 07 Nov, 2020
  • 1 location
None
A Study In Adults With Moderate To Severe Dermatomyositis

A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis

corticosteroids
dermatomyositis
rash
experimental drug
  • 122 views
  • 14 Oct, 2021
  • 48 locations
None
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder …

myopathy
corticosteroids
dermatomyositis
prednisolone
rash
  • 35 views
  • 14 Jun, 2021
  • 103 locations
None
Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis

18 and older with rheumatoid arthritis or idiopathic inflammatory myopathy (IIM). Healthy volunteers enrolled in protocol 01-M-0254 or 17-M-0181 are also needed. Design

myositis
weakness
myopathy
nonsteroidal anti-inflammatory drugs
anxiety
  • 36 views
  • 10 Oct, 2021
  • 1 location